Biograil Closes €20 Million Funding Round

Copenhagen/Bonn — Biograil ApS, a Copen­ha­­gen-based biotech company deve­lo­ping a unique oral device for admi­nis­te­ring thera­peu­tics that would other­wise require injec­tion, announ­ced the comple­tion of a 20 million euro funding round. Verve Ventures and Mega­trend Invest are back­ing the company, while HTGF—which led Biograil’s seed syndi­cate in 2019—is parti­ci­pa­ting through its growth fund, HTGF Opportunity.

The addi­tio­nal funding will support ongo­ing acti­vi­ties for the plan­ned Phase 1 clini­cal trials of BIONDD® in order to achieve key mile­sto­nes, such as noncli­ni­cal GLP studies, and to estab­lish the GMP manu­fac­tu­ring process ahead of a larger round of finan­cing in 2027.

Kars­ten Lind­hardt, CEO of Biograil: “It’s great to see such strong support from exis­ting inter­nal inves­tors and to have the HTGF Oppor­tu­nity growth fund parti­ci­pate in this round. Combi­ned with non-dilu­­tive finan­cing from part­ner­ships, this will enable Biograil to conti­nue advan­cing our BIONDD® tech­no­logy toward Phase 1 clini­cal trials. The BIONDD® tech­no­logy can enable the oral admi­nis­tra­tion of large-market compounds for grea­ter conve­ni­ence and medi­cal bene­fit, and further­more create deve­lo­p­ment oppor­tu­ni­ties for new, inno­va­tive combi­na­tion products that may never have been feasi­ble or attrac­tive as conven­tio­nal injec­ta­ble or oral products.”

Anke Caßing, Prin­ci­pal at HTGF:
“We first inves­ted in Biograil in 2019 because we reco­gni­zed the poten­tial of its approach to oral drug deli­very. Our parti­ci­pa­tion through the HTGF Oppor­tu­nity reflects our contin­ued confi­dence in this poten­tial as the company prepa­res for clini­cal development.”

About Biograil ApSB

iograil is a Copen­ha­­gen-based biotech company that deve­lops phar­maceu­ti­cal products based on BIONDD®. The device comes in a stan­­dard-sized capsule, Double Zero or Single Zero, and can deli­ver active thera­peu­tics to the gastric mucosa to effec­tively distri­bute them throug­hout the human body. Such thera­peu­tics may include products curr­ently on the market, inclu­ding injec­ta­ble drugs worth seve­ral billion dollars, or new chemi­cal compounds that cannot other­wise be admi­nis­te­red orally. The Biograil device uses a novel mecha­nism to faci­li­tate the effi­ci­ent deli­very of active ingredients—specifically biologics—into the stomach lining using a proprie­tary plat­form tech­no­logy manu­fac­tu­red via injec­tion molding. The team behind Biograil consists of expe­ri­en­ced entre­pre­neurs with exten­sive expe­ri­ence in foun­ding successful biotech compa­nies, as well as R&D execu­ti­ves respon­si­ble for the world’s first FDA-appro­­ved injec­­tion-molded oral tablet. — The Biograil inves­tor consor­tium includes Mega­trend Invest, Verve Ventures, High-Tech Grün­der­fonds, Eli Lilly and Co., Sanner Ventures, Evonik Venture Capi­tal, Anobis GmbH, and Roquette Ventures.

About Verve VenturesVer

ve Ventures is one of Europe’s most active deep-tech inves­tors. Foun­ded in Switz­er­land in 2010, Verve supports science-driven foun­ders from the seed stage onward in the fields of health and biotech, energy and resour­ces, and compu­ter and AI infra­struc­ture. With more than CHF 400 million in assets under manage­ment, Verve has achie­ved over 30 exits in global market leaders such as Apple, Ipsen, Ripple, and Essil­or­Lu­xot­tica. — https://www.verve.vc

About HTGF – High-Tech Gründerfonds

Germany and Europe need a new econo­mic miracle—we’re laying the foun­da­tion. We are Germany’s most active VC inves­tor, funding deep-tech, life-science, and digi­­tal-tech compa­nies that secure their tech­no­lo­gi­cal sove­reig­nty and expand their indus­trial strength. From the initial idea to inter­na­tio­nal scaling, we support bold foun­ders as a multi-stage VC platform—seamlessly, relia­bly, and for the long term. 350 active start­ups, 200+ exits, and 5 unicorns. Over €10 billion in follow-on funding mobi­li­zed. Toge­ther with DTCF, we repre­sent more than €3 billion in fund volume—and turn German and Euro­pean inno­va­tions into global tech champions.

Inves­tors in the HTGF Oppor­tu­nity growth fund include the ERP Special Fund and KfW, with funding from the Zukunfts­fonds (“Future Fund”). For more infor­ma­tion, visit HTGF.de, Linke­dIn, or the Zukunfts­fonds website. — www.htgf.de